Majeed Raphael W, Wilkins Martin R, Howard Luke, Hassoun Paul M, Anthi Anastasia, Cajigas Hector R, Cannon John, Chan Stephen Y, Damonte Victoria, Elwing Jean, Förster Kai, Frantz Robert, Ghio Stefano, Al Ghouleh Imad, Hilgendorff Anne, Jose Arun, Juaneda Ernesto, Kiely David G, Lawrie Allan, Orfanos Stylianos E, Pepe Antonella, Pepke-Zaba Joanna, Sirenko Yuriy, Swett Andrew J, Torbas Olena, Zamanian Roham T, Marquardt Kurt, Michel-Backofen Achim, Antoine Tobiah, Wilhelm Jochen, Barwick Stephanie, Krieb Phillipp, Fuenderich Meike, Fischer Patrick, Gall Henning, Ghofrani Hossein-Ardeschir, Grimminger Friedrich, Tello Khodr, Richter Manuel J, Seeger Werner
Department of Internal Medicine Universities of Giessen and Marburg Lung Center (UGMLC), German Center for Lung Research (DZL) Giessen Germany.
Institute of Medical Informatics RWTH Aachen University Aachen Germany.
Pulm Circ. 2022 Jul 1;12(3):e12123. doi: 10.1002/pul2.12123. eCollection 2022 Jul.
The Pulmonary Vascular Research Institute GoDeep meta-registry is a collaboration of pulmonary hypertension (PH) reference centers across the globe. Merging worldwide PH data in a central meta-registry to allow advanced analysis of the heterogeneity of PH and its groups/subgroups on a worldwide geographical, ethnical, and etiological landscape (ClinTrial. gov NCT05329714). Retrospective and prospective PH patient data (diagnosis based on catheterization; individuals with exclusion of PH are included as a comparator group) are mapped to a common clinical parameter set of more than 350 items, anonymized and electronically exported to a central server. Use and access is decided by the GoDeep steering board, where each center has one vote. As of April 2022, GoDeep comprised 15,742 individuals with 1.9 million data points from eight PH centers. Geographic distribution comprises 3990 enrollees (25%) from America and 11,752 (75%) from Europe. Eighty-nine perecent were diagnosed with PH and 11% were classified as not PH and provided a comparator group. The retrospective observation period is an average of 3.5 years (standard error of the mean 0.04), with 1159 PH patients followed for over 10 years. Pulmonary arterial hypertension represents the largest PH group (42.6%), followed by Group 2 (21.7%), Group 3 (17.3%), Group 4 (15.2%), and Group 5 (3.3%). The age distribution spans several decades, with patients 60 years or older comprising 60%. The majority of patients met an intermediate risk profile upon diagnosis. Data entry from a further six centers is ongoing, and negotiations with >10 centers worldwide have commenced. Using electronic interface-based automated retrospective and prospective data transfer, GoDeep aims to provide in-depth epidemiological and etiological understanding of PH and its various groups/subgroups on a global scale, offering insights for improved management.
肺血管研究所GoDeep元注册库是全球肺动脉高压(PH)参考中心的合作项目。将全球范围内的PH数据合并到一个中央元注册库中,以便在全球地理、种族和病因背景下对PH及其组/亚组的异质性进行高级分析(临床试验.gov NCT05329714)。回顾性和前瞻性PH患者数据(基于导管插入术诊断;排除PH的个体作为对照组合并)被映射到一个包含350多个条目的通用临床参数集,进行匿名处理并以电子方式导出到中央服务器。使用和访问由GoDeep指导委员会决定,每个中心有一票表决权。截至2022年4月,GoDeep包含来自8个PH中心的15742名个体和190万个数据点。地理分布包括来自美洲的3990名参与者(25%)和来自欧洲的11752名(75%)。89%被诊断为PH,11%被归类为非PH并作为对照组合并。回顾性观察期平均为3.5年(平均标准误差0.04),1159名PH患者随访超过10年。肺动脉高压是最大的PH组(42.6%),其次是2组(21.7%)、3组(17.3%)、4组(15.2%)和5组(3.3%)。年龄分布跨越几十年,60岁及以上患者占60%。大多数患者在诊断时具有中度风险特征。另外六个中心的数据录入正在进行中,并且已经开始与全球10多个中心进行谈判。GoDeep旨在通过基于电子接口的自动化回顾性和前瞻性数据传输,在全球范围内提供对PH及其各种组/亚组的深入流行病学和病因学理解,为改善管理提供见解。